IONTAS announces new antibody optimisation agreement with Teva Pharmaceuticals

Posted 29 July 2019

Share this article:

Press Release 

29 July 2019

IONTAS_logo

IONTAS announces new antibody optimisation agreement with Teva Pharmaceuticals

Cambridge, UK, 29 July 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced an agreement with Teva Pharmaceuticals (Teva) to apply its technologies and know-how to the optimisation of human antibodies for use as biotherapeutics.

 

Under the terms of the agreement, IONTAS will initially apply its proprietary technologies to provide Teva with a panel of optimised antibodies against a defined target. Teva will have the option to enter into further optimisation programmes in the future. The agreement also includes options for the screening of biophysical properties suitable for developable antibodies.

 

Dr John McCafferty, Founder and Chief Executive Officer of IONTAS, commented: “Our experience in both antibody discovery and optimisation enables us to generate antibodies that meet the stringent characteristics required by our Partners and the selection of IONTAS by Teva is a validation of this know-how and expertise. With our ability to focus on function, affinity, specificity and developability we can generate lead antibodies with a lower risk of Chemistry, Manufacturing and Controls issues.”


About IONTAS www.iontas.co.uk   

IONTAS is a biotechnology company focused on antibody discovery and cutting-edge technology development. IONTAS offers services for antibody discovery using Phage Display Technology; and the supply of bespoke phage display libraries. In addition, IONTAS offers proprietary antibody discovery platforms including Mammalian Display where full-length antibodies are expressed in the context of a mammalian cell thereby allowing selection based on function, stability, expression and developability; IONTAS have also developed a novel “KnotBody” format which facilitates the targeting of antibodies to ion channels, GPCRs and proteases.

About Teva www.tevapharm.com  

Teva Pharmaceutical Industries Ltd. has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and speciality medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of speciality and biopharmaceutical products. Learn more at www.tevapharm.com